TrialClinical lymphoma, myeloma & leukemia2019

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Brittany Knick Ragon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.